267
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

Clinicopathologic characteristics and survival of patients with primary effusion lymphoma

ORCID Icon, , , , & ORCID Icon
Pages 2093-2102 | Received 07 Oct 2019, Accepted 25 Apr 2020, Published online: 25 May 2020
 

Abstract

Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma confined to body cavities and universally associated with human herpesvirus type 8 infection. The prognosis of this entity remains poor, with a median survival time of 6 to 9 months. To better understand the clinicopathologic features of the disease and identify possible prognostic factors, we performed a systematic review of the literature for cases of PEL, including 2 previously unreported cases from our institution. PEL was more prevalent in men (92%), with a median age at diagnosis of 55 years. The median overall survival for the entire series was 6 months. Peritoneal involvement (HR:1.62; 95% CI:1.06–2.48) and elevated serum lactate dehydrogenase (LDH) levels (HR:2.50; 95% CI:1.21–5.19) were associated with higher risk of death, while pericardial involvement (HR:0.43; 95% CI:0.20–0.94) was associated with lower risk of death. Therefore, effusion site and serum LDH levels are potential prognostic factors in patients with PEL.

Acknowledgements

The authors would like to thank Sarah Bronson for his contributions to this manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.